Abatacept biosimilar - Momenta Pharmaceuticals

Drug Profile

Abatacept biosimilar - Momenta Pharmaceuticals

Alternative Names: M-834

Latest Information Update: 01 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Momenta Pharmaceuticals
  • Developer Momenta Pharmaceuticals; Mylan
  • Class Antipsoriatics; Antirheumatics; Eye disorder therapies; Immunoconjugates; Immunoglobulin fusion proteins
  • Mechanism of Action T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Autoimmune disorders; Inflammation

Most Recent Events

  • 21 Jul 2017 Momenta Pharmaceuticals and Mylan completes a phase I trial in Autoimmune disorders and Inflammation (In volunteers) in United Kingdom (NCT02923583)
  • 30 Jun 2017 Momenta Pharmaceuticals appeals the Patent Trial and Appeal Board's decision regarding validity of US patent 8 476 239 to the US Court of Appeals for the Federal Circuit
  • 30 Jun 2017 The US Court of Appeals for the Federal Circuit denies motion filed by Bristol Myers Squibb to dismiss Momenta Pharmaceuticals' appeal in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top